Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 434Osteosarcoma 131Sarcoma, Ewing 89Melanoma 81Rhabdomyosarcoma 78Neoplasms 70Gastrointestinal Stromal Tumors 63Neuroblastoma 62Bone Neoplasms 62Colorectal Neoplasms 60Breast Neoplasms 60Ovarian Neoplasms 58Glioblastoma 55Neoplasm Metastasis 52Liposarcoma 49Dendritic Cell Sarcoma, Interdigitating 44Carcinoma, Non-Small-Cell Lung 44Gliosarcoma 42Stomach Neoplasms 40Pancreatic Neoplasms 40Leiomyosarcoma 40Lymphoma 37Glioma 35Carcinoma, Renal Cell 35Sarcoma, Synovial 34Rhabdoid Tumor 34Neurofibrosarcoma 34Uterine Cervical Neoplasms 33Sarcoma, Kaposi 33Lymphoma, Non-Hodgkin 33

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Diseases × Sarcoma × 1 year × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡